ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

avacincaptad pegol

Also written as “Avacincaptad Pegol”, “Izervay™” and “Zimura”.

Its studies are mostly in Geographic Atrophy · Macular Degeneration · Polypoidal Choroidal Vasculopathy · Stargardt Disease, led by 2 companies.

Drug pageAvacincaptad pegol: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 6, 202511 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma101 open or runningphase 4since May 6, 2025Jul 1, 2008Jun 30, 2027phase 4 · NCT06970665
Hoffmann-La Rocheits history only10 open or runningphase 1since Apr 29, 2025Apr 29, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Astellas Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 1, 2008First study: phase 1 study in Neovascular Age-Related Macular DegenerationFirst studyNCT00709527 · 60 enrolled · United States
  2. Jul 30, 2009Phase 1 study in Dry Age-Related Macular DegenerationNCT00950638 · 47 enrolled · United States
  3. Mar 19, 2015Phase 2 study in Polypoidal Choroidal VasculopathyNCT02397954 · 4 enrolled · United States
  4. Jun 9, 2015Named avacincaptad pegolINNProposed as its International Nonproprietary Name in WHO's List 113
  5. Feb 16, 2016Phase 3 study in Geographic AtrophyNCT02686658 · 286 enrolled · United States, Croatia, Czechia and more
  6. Oct 30, 2017Phase 2 study in Neovascular Age-related Macular DegenerationNCT03362190 · 64 enrolled · United States, Hungary, Latvia
  7. Dec 1, 20172 phase 2 studiesNCT03364153, NCT03374670
  8. May 12, 2020Phase 3 study in Geographic AtrophyNCT04435366 · 448 enrolled · United States, Argentina, Australia and more
  9. Sep 7, 2022Phase 3 study in Geographic AtrophyNCT05536297 · 278 enrolled · United States, Argentina, Australia and more
  10. May 6, 2025Phase 4 study in Geographic AtrophyNCT06970665 · 17 enrolled · Japan

Ahead

  1. Jun 30, 2027Primary completion: phase 4 study in Geographic AtrophyNCT06970665

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 Astellas Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06970665Geographic Atrophy · Japan4Active, not recruitingJun 30, 202717
NCT05536297Geographic Atrophy · United States, Argentina, Australia and more3CompletedApr 10, 2025278
NCT04435366Geographic Atrophy · United States, Argentina, Australia and more3CompletedJul 25, 2022448
NCT03374670Polypoidal Choroidal Vasculopathy · United States2WithdrawnDec 20190
NCT03364153Stargardt Disease · United States, France, Germany and more2CompletedMar 31, 2025121
NCT03362190Neovascular Age-related Macular Degeneration · United States, Hungary, Latvia2CompletedOct 18, 201864
NCT02686658Geographic Atrophy · United States, Croatia, Czechia and more3CompletedSep 26, 2019286
NCT02397954Polypoidal Choroidal Vasculopathy · United States2CompletedOct 23, 20154
NCT00950638Dry Age-Related Macular Degeneration · United States1CompletedMar 24, 201147
NCT00709527Neovascular Age-Related Macular Degeneration · United States1CompletedDec 30, 200960

How it is read

Names in the registry

  • “Avacincaptad Pegol”, 6 entries
  • “avacincaptad pegol”, 3 entries
  • “Izervay™”, 1 entry
  • “Zimura”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.